IL1B and systemic-onset juvenile idiopathic arthritis: Apparently, at least in a significant subset of SJIA patients, the early phase of this disease is dominated by IL-1-dependent disease mechanisms, and early intervention by (first-line) therapeutic IL-1 blockade has resulted in excellent clinical outcomes [26,27].